Tatva Chintan Q2 Review - Robust Fundamentals; Major Contribution From Structured Directing Agents: KRChoksey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Tatva Chintan Pharma Chem Ltd.'s revenue reported at Rs 123.6 crore as against Rs 106.8 crore/Rs 60 crore in Q1 FY22 and Q2 FY21, respectively.
Ebitda reported at Rs 35.9 crore (up 38.9% QoQ/ up 463.8% YoY). Ebitda margin (excluding other income) improved to 29.0% on account of favorable product mix.
Tatva Chintan Pharma's employee expenses stood at Rs 7.5 crore and operating expenses at Rs 25.3 crore.
Profit before tax reported at Rs 35.4 crore. Profit before tax margin stood at 28.7%.
Profit after tax reported at Rs 32.4 crore. Profit after tax margin stood at 26.2% backed by lower effective tax rate, as Dahej facility enjoys zero tax on its export revenue.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.